Chemistry:JNJ-55308942
From HandWiki
Short description: Chemical compound
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C17H12F5N7O |
| Molar mass | 425.323 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
JNJ-55308942 is an investigational drug that works as a P2X7 antagonist with a downstream effect of reducing interleukin-1β release.[1][2][3] It is developed by Janssen Pharmaceuticals for bipolar depression.[4]
See also
References
- ↑ Bhattacharya, Anindya; Lord, Brian; Grigoleit, Jan-Sebastian; He, Yingbo; Fraser, Ian; Campbell, Shannon N.; Taylor, Natalie; Aluisio, Leah et al. (December 2018). "Neuropsychopharmacology of JNJ-55308942: evaluation of a clinical candidate targeting P2X7 ion channels in animal models of neuroinflammation and anhedonia". Neuropsychopharmacology 43 (13): 2586–2596. doi:10.1038/s41386-018-0141-6. ISSN 0893-133X. PMID 30026598.
- ↑ Bhattacharya, Anindya; Ceusters, Marc (January 2020). "Targeting neuroinflammation with brain penetrant P2X7 antagonists as novel therapeutics for neuropsychiatric disorders". Neuropsychopharmacology 45 (1): 234–235. doi:10.1038/s41386-019-0502-9. ISSN 0893-133X. PMID 31477815.
- ↑ Kolb, Hartmuth C.; Barret, Olivier; Bhattacharya, Anindya; Chen, Gang; Constantinescu, Cristian; Huang, Chaofeng; Letavic, Michael; Tamagnan, Gilles et al. (August 2019). "Preclinical Evaluation and Nonhuman Primate Receptor Occupancy Study of 18 F-JNJ-64413739, a PET Radioligand for P2X7 Receptors" (in en). Journal of Nuclear Medicine 60 (8): 1154–1159. doi:10.2967/jnumed.118.212696. ISSN 0161-5505. PMID 30733317.
- ↑ "CTG Labs - NCBI". https://clinicaltrials.gov/study/NCT05328297.
 |  |
